MARKET

MIST

MIST

Milestone Pharmaceuticals
NASDAQ
1.700
0.000
0.00%
After Hours: 1.695 -0.005 -0.29% 16:00 05/09 EDT
OPEN
1.710
PREV CLOSE
1.700
HIGH
1.710
LOW
1.672
VOLUME
21.12K
TURNOVER
0
52 WEEK HIGH
4.490
52 WEEK LOW
1.330
MARKET CAP
90.35M
P/E (TTM)
-1.2235
1D
5D
1M
3M
1Y
5Y
Milestone Pharmaceuticals Inc <MIST.OQ> expected to post a loss of 26 cents a share - Earnings Preview
Milestone Pharmaceuticals Inc expected to post a loss of 26 cents a share - Earnings Preview. The company is expected to show a fall in quarterly revenue when it reports results on May 9. LSEG's mean analyst estimate for the company is for a Loss of 26 cents per share.
Reuters · 2d ago
Weekly Report: what happened at MIST last week (0429-0503)?
Weekly Report · 3d ago
Weekly Report: what happened at MIST last week (0422-0426)?
Weekly Report · 04/29 09:02
Weekly Report: what happened at MIST last week (0415-0419)?
Weekly Report · 04/22 09:02
Milestone Pharmaceuticals To Present Data On Etripamil At The Preventative Cardiovascular Nursing Symposium
Milestone Pharmaceuticals Inc. Will present data on etripamil at the 30th Annual Cardiovascular Nursing Symposium on April 18-20th in Orlando, FL. The company is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines.
Benzinga · 04/17 12:12
Weekly Report: what happened at MIST last week (0408-0412)?
Weekly Report · 04/15 09:02
Milestone’s Etripamil Shows Promise in Self-Managed PSVT Treatment
TipRanks · 04/09 16:38
Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability To Self-Manage Recurring PSVT, Presented At The American College Of Cardiology Annual Meeting
Milestone Pharmaceuticals Inc. Announced new clinical data demonstrating real-world application of etripamil for conversion of recurrent paroxysmal supraventricular tachycardia. The drug is an investigational new drug for the acute treatment of PSVT. The study was presented at the American College of Cardiology Scientific Sessions.
Benzinga · 04/08 15:37
More
About MIST
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.

Webull offers Milestone Pharmaceuticals Inc stock information, including NASDAQ: MIST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MIST stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MIST stock methods without spending real money on the virtual paper trading platform.